APYX MEDICAL CORPORATION RECEIVES FDA 510(K) CLEARANCE FOR THE USE OF RENUVION TO COAGULATE AND CONTRACT SOFT TISSUES, INCLUDING SUBCUTANEOUS TISSUE, WHERE NEEDEDBy ApyxMedical|2025-12-12T19:05:39-05:00February 27, 2023|
APYX MEDICAL CORPORATION ANNOUNCES NEW FIVE-YEAR CREDIT AGREEMENT WITH MIDCAP FINANCIALBy ApyxMedical|2025-12-12T19:06:56-05:00February 21, 2023|
APYX MEDICAL CORPORATION TO RELEASE FOURTH QUARTER AND FISCAL YEAR 2022 FINANCIAL RESULTS ON MARCH 16, 2023By ApyxMedical|2025-12-12T19:07:24-05:00February 16, 2023|
RENUVION COSMETIC NECK LAXITY PROCEDURE TO BE FEATURED ON ‘THE BALANCING ACT’ TALK SHOW ON LIFETIME FEBRUARY 13By ApyxMedical|2025-12-12T19:07:54-05:00February 9, 2023|
APYX MEDICAL CORPORATION ANNOUNCES FDA 510(K) SUBMISSION FOR THE USE OF THE RENUVION APR HANDPIECE FOR THE COAGULATION OF SUBCUTANEOUS SOFT TISSUES WHERE NEEDED, FOLLOWING LIPOSUCTIONBy ApyxMedical|2025-12-12T19:08:24-05:00February 1, 2023|
